S. 641

119th Congress

In Committee

Safe and Affordable Drugs from Canada Act of 2025

Sponsored byDemocrat:Sen. Klobuchar, Amy [D-MN]MN· Introduced 19 février 2025

7

Cosponsors

2

Actions

0

Amendments

0

Committees

Since introduced

Introduced
Committee
Passed Chamber
Passed Both
Enacted
Step 1 of 0
Latest action

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

19 février 2025·1 year ago

Summary

Introduced in Senate · Updated 14 mai 2025

Safe and Affordable Drugs from Canada Act of 2025

This bill requires the Food and Drug Administration (FDA) to allow for the personal importation of prescription drugs from Canada in certain instances.

Such a drug must (1) be purchased from an approved Canadian pharmacy and dispensed by a pharmacist licensed in Canada; (2) be purchased by an individual for personal use only and in quantities not to exceed a 90-day supply; (3) be filled using a valid prescription from a physician licensed in a U.S. state; and (4) have the same active ingredients, route of administration, dosage form, and strength as an FDA-approved drug. Certain types of drugs may not be imported under this program, such as controlled substances, biological products, or intravenously injected drugs.

An approved pharmacy under this program must be located and licensed in Canada and meet additional requirements, such as participation in ongoing and comprehensive quality assurance programs.

The FDA must publish a list of approved Canadian pharmacies on its website.

Timeline

2 actions

  1. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    19 février 2025 · IntroReferral

  2. Introduced in Senate

    19 février 2025 · IntroReferral

Sponsorship

7 cosponsors

Sponsor

Democrat:Sen. Klobuchar, Amy [D-MN]MN

Cosponsors

  • Democrat571%
  • Republican114%
  • Independent114%

Classification

Policy area

Health

Legislative subjects

Administrative law and regulatory proceduresCanadaDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationGovernment information and archivesPrescription drugsTrade restrictions
Pelosi Tracker
© 2026 - Tous droits réservés. Propulsé par Vantara Labs
Ce site web est une plateforme indépendante et tierce. Il n'est pas affilié à, approuvé par ou associé de quelque manière que ce soit à Nancy Pelosi, son bureau ou ses représentants. Toute utilisation de son nom est uniquement à des fins de discussion d'informations publiques disponibles.Les informations fournies sur ce site web sont uniquement à des fins informatives et éducatives et ne sont pas destinées à servir de conseils financiers ou d'investissement, ni ne doivent être interprétées comme tels. Les données présentées ici proviennent de déclarations et dossiers publics. Bien que nous nous efforcions d'assurer l'exactitude, l'actualité et l'exhaustivité, nous ne garantissons pas que toutes les informations sont exemptes d'erreurs ou à jour.Le support est disponible en anglais. Certaines traductions sont automatiques.